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Are HIV-infected patients candidates for liver transplantation?q
Pierre-Alain Clavien*
Swiss HPB (Hepato-Pancreato-Biliary) Center, Department of Surgery, University Hospital Zu¨rich, Raemistrasse 100,
CH-8091 Zu¨rich, SwitzerlandSince 2005, we have published a series of ‘‘Forum on
Liver Transplantation” covering a number of controver-
sial topics ranging from issues related to hepatitis C [1],
cancer [2–4], surgical aspects including the use of living
[5] or ‘‘marginal” [6] donors, acute liver failure [7] or even
on issues related to the best institutional setting providing
an optimal framework, e.g., center approach, to treat
patients with liver diseases [8]. Each forumwas comprised
of a series of 4–5 articles, inwhich established expertswere
selected to address a speciﬁc question on a controversial
topic. Starting from the 10th forum, we will switch to a
diﬀerent format, whereby an expert (ﬁrst author) will be
responsible for a single article to coordinate the entire
forum, with international colleagues chosen based on
their scientiﬁc contribution to the ﬁeld. In contrast to
many other reviews, co-authorship with junior members
in this new format will be avoided to present a ‘‘Forum”
based on the sole opinion of ‘‘established” experts.
Forum 10, the ﬁrst one of this new format, has been
prepared by Didier Samuel, from Paul Brousse Hospi-
tal, Paris, whose task involved addressing the controver-
sial issues of liver transplantation in the HIV-infected
population. The topic is very timely due to the increas-
ing prevalence of co-infection with hepatitis viruses B0168-8278/$34.00  2008 European Association for the Study of the Liver.
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virus; DNA, deoxyribonucleic acid.and C, the advent of new antiviral strategies, both
against HIV and hepatitis B and C, and the increasing
panel of available anti-rejection drugs after transplanta-
tion. Recent reports in this ﬁeld justiﬁed this discussion
with the aim to also highlight areas requiring further
investigation.
RainerWeber, from the University of Zu¨rich, Switzer-
land, covers the epidemiology of the 32 millions of HIV-
infected patients worldwide, highlighting that the search
for a vaccine has failed so far, and that, unfortunately,
there is still no credible expectation about when one will
become available [9]. In a large cohort of patients, the
most frequent cause of non-AIDS related deaths in this
population was liver disease, related in more than three-
quarters of cases to chronic hepatitis B andC co-infection
[10]. Peter Stock from the University of California in San
Francisco, USA, is the principal investigator of a large
NIH sponsored study on the role of liver transplantation
in HIV-infected patients. In a comprehensive discussion,
Dr. Stock presents the criteria to optimally select patients
for liver transplantation. Rigid rules such as a CD4+
counts >200 cell/mL should be avoided, as the presence
of portal hypertension with hypersplenism and the use
of IFN therapy in HCV-infected patients may cause fur-
ther decreases in CD4+ counts, unrelated to HIV infec-
tion [11]. Similarly, opportunistic infection, once
considered as an absolute contraindication, must be eval-
uated in light of the chance for the patient to reconstitute
an immune response with antiretroviral therapies and
appropriate antibiotic treatment. On the other hand, care
should be taken to avoid transplantation in a patient with
very poor liver reserve, i.e., high MELD score, particu-
larly in theHCVpopulation.At this point, the singlemost
important factor in dealing with these complex patients isPublished by Elsevier B.V. All rights reserved.
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positive population. Another controversial issue is the
choice of the immunosuppressive regimen following
OLT. This part, covered by Jean-Charles Duclos-Valle´e,
indicates that not much convincing data are currently
available in this area. Two principles should, perhaps,
trigger special attention: ﬁrst, the avoidance of a rapid
withdrawal of steroids [12], particularly in the HCV pop-
ulation, due to the evidence of accelerated ﬁbrosis, and
second, great care should be taken in managing potential
interaction among antiviral and immunosuppressive
drugs. Finally, Norah Terrault, from the University of
California in San Francisco, USA, provides an excellent
discussion related to the management of such patients
before and after OLT. She emphasises the need for the
early referral of co-infected HIV patients with hepatitis
viruses B and C to transplant centers, as the severity of
the disease and the nature of liver decompensationmostly
inﬂuence the results of OLT in this population [13]. In
HBVpatients, themain pre-transplant strategy is to reach
a low level of HBV DNA at the time of surgery, and in
HCV patients, to prevent the rapid aggravation of the
liver function (e.g. child C or high MELD score), which
could be achieved, for example, by using a living donor.
I thank Didier Samuel for the excellent and critical
coverage of this complex ﬁeld with the help of interna-
tional experts. I hope that this new format will help cli-
nicians to better evaluate this diﬃcult population of
patients for OLT.
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